Brooklyn ImmunoTherapeutics Inc. [AMEX: BTX] price surged by 29.49 percent to reach at $3.68. The company report on April 20, 2021 that Brooklyn ImmunoTherapeutics Reports Inducement Grants.
Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, announced that on 16 April 2021, Dr. Federoff was granted a nonqualified stock option covering 2,627,915 shares of Brooklyn’s common stock (the “Time-Based Option”).
The Time-Based Option will have a per share exercise price equal to the closing price of a share of Brooklyn’s common stock on the NYSE American Stock Exchange on 16 April 2021. Of the shares covered by the Time-Based Option, 656,979 will vest on April 16, 2022, 54,748 will vest on the sixteenth day of each month from May 2022 through March 2025, and the remaining 54,756 will vest on April 16, 2025, in each case for so long as the Dr. Federoff provides continuous service to Brooklyn through the relevant vesting date.
A sum of 18460178 shares traded at recent session while its average daily volume was at 2.32M shares. Brooklyn ImmunoTherapeutics Inc. shares reached a high of $18.87 and dropped to a low of $11.35 until finishing in the latest session at $16.16.
Guru’s Opinion on Brooklyn ImmunoTherapeutics Inc. [BTX]:
The Average True Range (ATR) for Brooklyn ImmunoTherapeutics Inc. is set at 2.06, with the Price to Sales ratio for BTX stock in the period of the last 12 months amounting to 89.33. The Price to Book ratio for the last quarter was 27.86, with the Price to Cash per share for the same quarter was set at 0.02.
BTX Stock Performance Analysis:
Brooklyn ImmunoTherapeutics Inc. [BTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 103.53. With this latest performance, BTX shares gained by 202.62% in over the last four-week period, additionally plugging by 286.60% over the last 6 months – not to mention a rise of 634.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BTX stock in for the last two-week period is set at 76.65, with the RSI for the last a single of trading hit 83.19, while it was recorded at 11.00 for the last single week of trading.
Insight into Brooklyn ImmunoTherapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Brooklyn ImmunoTherapeutics Inc. [BTX] shares currently have an operating margin of -93.09 and a Gross Margin at +46.41. Brooklyn ImmunoTherapeutics Inc.’s Net Margin is presently recorded at -76.12.
Return on Total Capital for BTX is now -76.52, given the latest momentum, and Return on Invested Capital for the company is -94.09. Return on Equity for this stock declined to -148.60, with Return on Assets sitting at -45.35. When it comes to the capital structure of this company, Brooklyn ImmunoTherapeutics Inc. [BTX] has a Total Debt to Total Equity ratio set at 245.59. Additionally, BTX Total Debt to Total Capital is recorded at 71.06, with Total Debt to Total Assets ending up at 49.83. Long-Term Debt to Equity for the company is recorded at 62.59, with the Long-Term Debt to Total Capital now at 18.09.
Reflecting on the efficiency of the workforce at the company, Brooklyn ImmunoTherapeutics Inc. [BTX] managed to generate an average of -$200,682 per employee. Receivables Turnover for the company is 8.85 with a Total Asset Turnover recorded at a value of 0.60.Brooklyn ImmunoTherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.70.
Brooklyn ImmunoTherapeutics Inc. [BTX] Insider Position Details
There are presently around $1 million, or 0.20% of BTX stock, in the hands of institutional investors. The top three institutional holders of BTX stocks are: EAGLE ASSET MANAGEMENT INC with ownership of 35,162, which is approximately New of the company’s market cap and around 8.10% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 10,590 shares of the stock with an approximate value of $0.17 million in BTX stocks shares; and NORTH STAR INVESTMENT MANAGEMENT CORP., currently with $0.15 million in BTX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Brooklyn ImmunoTherapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 4 institutional holders increased their position in Brooklyn ImmunoTherapeutics Inc. [AMEX:BTX] by around 44,679 shares. Additionally, 4 investors decreased positions by around 63,564 shares, while 7 investors held positions by with 33,733 shares. The mentioned changes placed institutional holdings at 74,510 shares, according to the latest SEC report filing. BTX stock had 3 new institutional investments in for a total of 43,993 shares, while 4 institutional investors sold positions of 63,564 shares during the same period.